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Background: Chromosome instability manifests as an abnormal chromosome complement and is a pathogenic
event in cancer. Although a correlation between abnormal chromosome numbers and cancer exist, the underlying
mechanisms that cause chromosome instability are poorly understood. Recent data suggests that aberrant sister
chromatid cohesion causes chromosome instability and thus contributes to the development of cancer. Cohesion
normally functions by tethering nascently synthesized chromatids together to prevent premature segregation and
thus chromosome instability. Although the prevalence of aberrant cohesion has been reported for some solid
tumors, its prevalence within liquid tumors is unknown. Consequently, the current study was undertaken to
evaluate aberrant cohesion within Hodgkin lymphoma, a lymphoid malignancy that frequently exhibits
chromosome instability.
Methods: Using established cytogenetic techniques, the prevalence of chromosome instability and aberrant
cohesion was examined within mitotic spreads generated from five commonly employed Hodgkin lymphoma cell
lines (L-1236, KM-H2, L-428, L-540 and HDLM-2) and a lymphocyte control. Indirect immunofluorescence and
Western blot analyses were performed to evaluate the localization and expression of six critical proteins involved in
the regulation of sister chromatid cohesion.
Results: We first confirmed that all five Hodgkin lymphoma cell lines exhibited chromosome instability relative to
the lymphocyte control. We then determined that each Hodgkin lymphoma cell line exhibited cohesion defects
that were subsequently classified into mild, moderate or severe categories. Surprisingly, ~50% of the mitotic
spreads generated from L-540 and HDLM-2 harbored cohesion defects. To gain mechanistic insight into the
underlying cause of the aberrant cohesion we examined the localization and expression of six critical proteins
involved in cohesion. Although all proteins produced the expected nuclear localization pattern, striking differences
in RAD21 expression was observed: RAD21 expression was lowest in L-540 and highest within HDLM-2.
Conclusion: We conclude that aberrant cohesion is a common feature of all five Hodgkin lymphoma cell lines
evaluated. We further conclude that aberrant RAD21 expression is a strong candidate to underlie aberrant cohesion,
chromosome instability and contribute to the development of the disease. Our findings support a growing body of
evidence suggesting that cohesion defects and aberrant RAD21 expression are pathogenic events that contribute
to tumor development.
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For over a century, it has been suggested that abnormal
chromosome numbers are a pathogenic event that are
associated with and drive cancer development [1]. Exten-
sive studies have confirmed that virtually all tumor types,
including solid (e.g. colorectal cancer [2]) and liquid (e.g.
Hodgkin lymphoma [3]), exhibit genomic instability that
often manifests as chromosome instability (CIN). CIN is
a dynamic process that is defined by an increased rate
at which whole chromosomes or large parts thereof
are gained or lost [4], consequently aneuploidy is now
employed as a metric for CIN. Conceptually, CIN pro-
motes tumor heterogeneity by increasing numerical or
structural chromosomal changes that in turn impacts
oncogene and/or tumor suppressor gene copy numbers
[5]. Thus, CIN is a driver of the tumorigenic process [6] and
often arises through defects in DNA repair, DNA replication
or chromosome segregation [2,7-9]. Tumors displaying
CIN (i.e. an aneuploid karyotype) are associated with
poor prognosis, and the rapid acquisition of multidrug
resistance [10-12]. Despite the strong correlation between
CIN and tumors, very little is known about the underlying
aberrant genes and/or mechanisms that account for the
CIN phenotype.
A recent body of evidence has begun to emerge sug-
gesting that aberrant sister chromatid cohesion may be a
pathogenic event that underlies CIN and drives tumor
development. Sister chromatid cohesion is an evolu-
tionarily conserved biological process that ensures the
faithful segregation of genomic DNA from mother to
daughter cells. Classically, cohesion serves to prevent
premature chromosome segregation during mitosis by
tethering newly synthesized sister chromatids together
prior to entry into anaphase [13], however it also func-
tions in DNA repair [14] and gene expression [15]. Mitotic
cohesion is effected by a quaternary complex referred to
as cohesin [13], which is comprised of SMC1A, SMC3,
RAD21 and STAG1/STAG2/STAG3. Cohesin is initially
loaded onto DNA in G1 by cohesin loaders (NIPBL and
MAU2), but isn’t established until S-phase when SMC3
is acetylated by ESCO1 and ESCO2 [16]. Although the
exact mechanism (i.e. structure) by which cohesin tethers
the sister chromatids is unclear, it is believed to form a
‘ring-like’ structure that encircles the two DNA strands
[17]. During the initial stages of mitosis (prophase to
metaphase), cohesion is first lost along the length of
the chromosome arms but is maintained/protected at
the centromeres through a Shugoshin-dependent mechan-
ism [18]. A critical requirement of the metaphase to
anaphase transition is the regulated cleavage of the
remaining centromeric cohesion prior to chromosome
segregation. Cohesion cleavage, specifically RAD21 cleav-
age, is mediated by Separase (ESPL1), a protease that is
normally held in check by Securin (PTTG1), which israpidly degraded via a ubiquitin-mediated process or-
chestrated by APC/C-CDC20.
DNA re-sequencing efforts have determined that defects
in cohesin and cohesion-related genes are implicated in
various syndromes and diseases including cancer. Defects
in NIPBL, SMC1A, and SMC3 for example, are pathogenic
in Cornelia de Lange syndrome, a rare genetic disorder
associated with growth and cognitive impairment and a
shortened lifespan (reviewed in [19]). Interestingly, indi-
viduals with Cornelia de Lange syndrome do not appear
to have a predisposition to develop cancer, but this may
be due to the shortened lifespan associated with a severe
disease state. Still, rare cases of Wilm’s tumors and liver
hemangioendothelioma have been identified in autopsies
[20]. Somatic alterations in cohesion-related genes (e.g.
SMC1A, SMC3, STAG2, RAD21, etc.) have however, been
identified in a large number of CIN tumor types. Homozy-
gous deletions, amplifications and single nucleotide poly-
morphisms, which presumably impact expression and/or
function and ultimately sister chromatid cohesion have
been identified in various cancers including breast, ovar-
ian, colorectal, lung cancer, melanoma, Ewing’s sarcoma,
acute myeloid leukemia, myeloid diseases and endometrial
cancers [2,7-9,21-28]. Indeed, we recently demonstrated
that diminished expression of a subset of these genes
caused aberrant mitotic cohesion and CIN [7]. Collect-
ively, these data suggest that altered expression and/or
function of key cohesion-related genes are pathogenic
events that underlie CIN and thus contribute to the de-
velopment of cancer. However, it is currently unclear
how pervasive and prevalent aberrant cohesion is within
tumors, specifically within those that frequently exhibit
CIN such as Hodgkin lymphoma (HL).
HL is a malignant proliferation of lymphoid cells that
frequently exhibits CIN and extensive cytogenetic ana-
lyses have routinely identified numerical (and structural)
changes in chromosomes within both HL patient sam-
ples and cell lines [29-31]. Although there is evidence
implicating aberrant telomere biology in the etiology of
HL [32-35], the prevalence of aberrant sister chromatid
cohesion in HL has never been examined. In the present
study, we examined the prevalence of aberrant sister
chromatid cohesion within five common HL cell lines
and a lymphocyte control. Using cytogenetic techniques,
we first established the chromosome distribution profile
and modal chromosome number for each line, and sub-
sequently interrogated mitotic spreads for the presence
of aberrant cohesion. Surprisingly, all HL lines exhibited
aberrant cohesion and strikingly two lines, L-540 and
HDLM-2, harbored cohesion defects in ~50% of all mitotic
spreads examined. To identify the underlying mechanism
that accounts for the aberrant cohesion, the localization
and expression pattern of six key cohesion proteins,
SMC1A, SMC3, STAG2, RAD21, Securin and Separase,
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nuclear localization patterns within each line examined,
there was significant variability in the level of RAD21 ex-
pression. Of particular interest, was the observation that
RAD21 exhibit the greatest variation within these lines and
in fact, it was lowest within L-540 and highest within
HDLM-2 cell lines. Our results demonstrate that aber-
rant cohesion is a common feature of all five HL lines
evaluated, and further suggest that aberrant RAD21 ex-
pression is a causative agent that contributes to the CIN
phenotype, particularly within the L-540 and HDLM-2
cell lines. Collectively, our data support recent findings
implicating aberrant cohesion as a significant pathogenic
factor in the development of various tumor types, which
now includes HL.
Methods
Cell lines and culture
The five HL cell lines, L-1236 (DSMZ; ACC-530), KM-H2
(DSMZ; ACC-8), L-428 (DSMZ; ACC-197), L-540 (DSMZ;
ACC-72), and HDLM-2 (DSMZ; ACC-17) were cultured
in RPMI-1640 (HyClone) medium supplemented with
10% fetal bovine serum (Sigma) in humidified incubator
maintained at 37°C with 5% CO2. Cell lines were authenti-
cated on the basis of recovery, viability, growth, and
morphology. A blood sample was obtained with consent
from a healthy volunteer by venipuncture and drawn
into collection tubes containing heparin (BD Biosciences).
Written informed consent was obtained, as approved by
CancerCare Manitoba (Manitoba Institute of Cell Biology)
and the University of Manitoba Ethics Review Committees
in accordance with the Declaration of Helsinki. Control
lymphocytes were isolated from the blood sample. The
sample was centrifuged for 10 minutes at 1,500 rpm,
and lymphocytes were collected and added to 30 ml of
culture medium (RPMI-1640) supplemented with 10%
fetal bovine serum containing penicillin/streptomycin.
To stimulate proliferation of lymphocytes so that mi-
totic preparations could be generated, phytohemagglu-
tinin (5 μg/ml; Invitrogen) was added to lymphocytes
for 72 h (37°C).
Mitotic chromosome spreads and enumeration
To enrich for mitotic chromosomes, asynchronous and
subconfluent cells were treated with KaryoMax colcemid
(0.1 mg/ml; Invitrogen) for 2 h prior to harvesting. Mitotic
chromosome spreads were prepared as described previ-
ously [7], with the hypotonic (75 mM KCl) treatment
extended to 15 minutes. Slides containing chromo-
some spreads were counterstained in Vectashield (Vector
Laboratories) containing DAPI and a minimum of 300
mitotic spreads of either control or each HL cell line were
imaged. Imaging was performed on an AxioImager 2
(Zeiss) equipped with an AxioCam HR charge-coupleddevice (CCD) camera (Zeiss) and a 63× oil immersion
plan-apochromat lens (1.4 numerical aperture). Images
were acquired with AxioVision software and saved as 16-
bit Tif images. Images were enumerated and the total num-
ber of chromosomes from each mitotic spread was manually
determined. All data were exported into Prism v6
(GraphPad) where the modal chromosomal number and
chromosome distribution frequencies were determined.
The normal chromosomal distribution range for each cell
line was operationally defined as the chromosomal distri-
bution observed between the 25th and 75th percentiles of
the total distribution.Cohesion assay
Mitotic chromosome spreads were generated and imaged
as detailed above and cohesion was evaluated at the pri-
mary constriction (i.e. centromere) as previously described
[7]. Similar assays have been used previously to investigate
sister chromatid cohesion. Cohesion was categorized into
normal (cohesed) or aberrant (primary constriction gap;
PCG). PCG is defined as a visually appreciable gap be-
tween the sister chromatids within the DAPI channel.
Chromosome spreads exhibiting PCGs were further classi-
fied into one of three categories based on the severity and
frequency of the PCGs within a given mitotic spread. We
define the 3 aberrant PCG categories as; 1) PCGI (mild),
1–4 chromosomes exhibit PCGs but are still in close
proximity, 2) PCGII (moderate), ≥5 chromosomes ex-
hibit PCG but are still in close proximity, and 3) PCGIII
(severe), all cohesion appears to be lost as chromatids
appear randomly distributed throughout the spread).
Finally, the frequencies of normal and aberrant cohesion
were calculated and tables and graphs were generated.Indirect immunofluorescence
Indirect immunofluorescence labeling of cells was per-
formed as detailed previously [36,37] with slight modifi-
cations. Briefly, asynchronous cells were harvested by
centrifugation (180×g for 5 minutes), counted with a
Coulter counter (BD), and resuspended in PBS to a final
concentration of 107 cell/ml. Approximately 106 cells were
spun (250 rpm; 5 minutes) onto glass slides using a Shandon
CytoSpin 4 (Thermo Scientific). Cells were fixed with 4%
paraformaldehyde, permeablized, immunofluorescently
labeled and mounted in Vectashield (Vector Labs) con-
taining DAPI. A list of the primary antibodies and work-
ing dilutions are indicated in Additional file 1: Table S1.
All primary antibodies were visualized through the addition
of either goat anti-rabbit Alexafluor488 (Invitrogen), goat
anti-mouse Cy3 (Jackson ImmunoResearch Laboratories,
Inc.), or donkey anti-goat FITC (Jackson ImmunoResearch
Laboratories, Inc.) antibodies diluted at 1:200. Images
were acquired as above and representative images were
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(Adobe) where panels were assembled.
Immunoblot analysis
Immunoblots were performed on proteins extracted from
lymphocytes obtained from healthy donors, and asyn-
chronous and subconfluent cells of all five HL cell lines as
described previously [38]. A list of the primary antibodies
and working dilutions are indicated in Additional file 1:
Table S1. Anti-rabbit (1:15,000), anti-mouse (1:10,000) or
anti-goat (1:10,000) antibodies conjugated with horse-
radish peroxidase (Jackson ImmunoResearch Laborator-
ies, Inc.) were employed to detect the primary antibodies
by standard chemiluminescence. Blots were stripped and
reblotted with an anti-α-tubulin mouse monoclonal anti-
body (Abcam ab7291 at 1:10,000) as a loading control.
Figures were assembled in Photoshop and ImageJ (gel
analyzer tool) was employed to determine the relative
signal intensities of bands in a semi-quantitative fashion.
All semi-quantitative data were normalized to the corre-
sponding α-tubulin loading control for each lane and the
relative fold differences in expression were determined.
Results
HL cell lines are aneuploid and exhibit a CIN phenotype
As CIN is a dynamic process that drives karyotypic evolu-
tion, it was first essential to characterize the chromosome
number and distribution for each cell line and control
employed. We purposely limited our study to five com-
monly employed HL cell lines L-1236, KM-H2, L-428,
L-540 and HDLM-2, as each is reported to have an
aneuploid (i.e. CIN) karyotype [39-41], while lymphocytes
isolated from a normal, healthy donor were used as the
control and are expected to have normal cohesion and a
diploid karyotype. Mitotic chromosome spreads were
generated as detailed in Methods, and chromosomes were
enumerated from a minimum of 300 spreads (Table 1). As
expected, all five HL cell lines were aneuploid relative to
the diploid control, with the modal chromosome numbers
ranging from hypodiploid for HDLM-2 (modal number =
36 chromosomes), to hypotriploid for L-540 (56 chro-
mosomes), KM-H2 (61 chromosomes), and L-1236 (65Table 1 Characterization of chromosome distribution frequen
Cell line NA Total chromosome range M
Control 300 46-47 4
HDLM-2 300 31-123 3
KM-H2 325 41-143 6
L-428 319 45-186 9
L-540 348 41-148 5
L-1236 310 41-138 6
ATotal number of mitotic chromosome (Chr.) spreads evaluated.
BNormal Chromosome Range is defined as the 25th to 75th percentile of the total chchromosomes), to hypotetraploid for L-428 (91 chromo-
somes). Moreover, the total chromosome distribution
ranges were dramatically larger for each of the five HL
cell lines relative to the control as were the normal dis-
tribution ranges (as defined by the 25th to 75th percentile),
thus confirming the five HL cell lines exhibit CIN
phenotypes and are aneuploid.
Aberrant sister chromatid cohesion is common to all HL
cell lines examined
Having established that each of the HL cell lines exhibit
CIN, we now wished to examine whether sister chroma-
tid cohesion, as measured by primary constriction
cohesion, was normal or aberrant within each line. We
have previously defined aberrant cohesion or primary
constriction gaps (PCG) as a clear and distinct separ-
ation within the DAPI signal occurring between the
sister chromatids at the centromere, the site of the pri-
mary constriction (Figure 1A; top left quadrant) [7]. PCGs
were manually assessed in a minimum of 300 mitotic
spreads generated from each HL cell line and control. Sur-
prisingly, all HL cell lines had striking increases in PCG
frequencies relative to the lymphocyte control (Figure 1B
and Table 2) that range from 10.2% in KM-H2 to 55.4% in
L-540. Of particular note, ~50% of all spreads evaluated
from L-540 (55.4%) and HDLM-2 (49.3%) exhibited PCGs,
which is ~160-fold greater than the control in which only a
single chromosome within a single spread exhibited a
mild PCG phenotype.
To further characterize the severity of the PCG pheno-
types, all spreads exhibiting aberrant cohesion were further
classified into three distinct sub-categories (Figure 1A)
ranging from mild (PCGI) to moderate (PCGII) to severe
(PCGIII) (see Methods for definitions). Interestingly, all
five HL cell lines harbored mitotic spreads within each
of the three aberrant cohesion categories (Table 2), while
only one chromosome from a single spread exhibited a
mild cohesion defect (i.e. PCGI) representing a baseline
frequency of ~7.2x10-5 cohesion defects/chromosome
(1/[300 spreads × 46 chromosomes]). Further scrutiny
of only those mitotic spreads with PCGs revealed that
with the exception of L-540, PCGI was the most prevalentcies in various HL cell lines







romosome distribution range on the given cell line.
Figure 1 HL cell lines exhibit cohesion defects. (A) Representative images of mitotic chromosome spreads from the L-540 cells demonstrating
normal primary constriction cohesion (Upper left) and the various categories of aberrant cohesion; PCGI (Mild), PCGII (Moderate), and PCGIII
(Severe). Each cohesion category (quadrant) contains a low-resolution DAPI image of the entire mitotic spread. Each spread contains a white
bounding box that defines the region magnified and presented on the right-hand side of each quadrant. Scale bar represents 10 μm.
(B) Graphs depicting the total fraction of cells with aberrant cohesion; white (normal), black (aberrant). The total number of mitotic
spreads evaluated for each cell line is indicated at the bottom of each column. (C) Graphical depiction for only the fraction of mitotic spreads with
cohesion defects. The frequencies of defects are classified according to three different aberrant cohesion categories (e.g. PCGI - light gray; PCGII - dark
gray; and PCGIII - black). The total number of mitotic spreads exhibiting aberrant cohesion is indicated at the base of each column.
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L-1236 to 80.5% in HDLM-2 (Figure 1C). In L-540, the
most prevalent aberrant category was PCGIII (53.9%).
Of particular note is the inverse relationship that was
observed between the two cell lines with the greatest
abundance of aberrant cohesion (L-540 and HDLM-2).
The most frequently observed aberrant category in L-540
is PCGIII (severe) while in HDLM-2 it is PCGI (mild),suggesting that the aberrant mechanism(s) underlying the
cohesion defects may be different.
Altered RAD21 expression is associated with elevated
cohesion defects
We now wished to investigate the underlying mecha-
nisms that account for the aberrant cohesion observed
within the HL lines, with a particular focus on HDLM-2
Table 2 Frequency of primary constriction gaps in various
HL cell lines
Cell line NA Normal
cohesion
(%)
Primary constriction gap (PCG) (%)
PCGI PCGII PCGIII Total
B
Control 300 99.7 0.3 0.0 0.0 0.3
HDLM-2 300 50.7 39.7 8.3 1.3 49.3
KM-H2 325 89.8 6.5 2.5 1.2 10.2
L-428 319 84.7 7.5 0.6 7.2 15.3
L-540 348 44.6 14.9 10.6 29.9 55.4
L-1236 310 86.5 4.8 3.9 4.8 13.5
AN; total number of chromosome spreads evaluated.
BRefers to the total number of cohesion defects (i.e. PCGI + PCGII + PCGIII).
Figure 2 Spatial localization of cohesion-related proteins in
L-540 cells. Indirect immunofluorescence was employed to
determine the spatial localization of six proteins involved in sister
chromatid cohesion (SMC1A, SMC3, STAG2, RAD21, Securin and
Separase). Presented are representative high-resolution (63×)
images obtained from L-540 cells in interphase. Nuclei were
counterstained with DAPI and immunofluorescently labeled for
the epitope indicated on the left. Scale bar represents 3 μm.
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within those lines. We purposefully restricted our ana-
lysis to six candidates that are central to cohesion, and
that have been implicated in the pathogenesis of other
tumor types [7,42,43]. Included in this list are the four
members of the cohesin complex, SMC1A, SMC3, RAD21
and STAG2, as well as Securin and Separase, which
regulate cohesin cleavage. As an initial step, we first
surveyed the Broad-Novartis Cancer Cell Line Encyclopedia
(http://www.broadinstitute.org/ccle/home) and failed to
identify a single somatic mutation within any of the six
candidate genes in any of the five HL cell lines (data not
shown). However, the possibility remained that the HL
lines we employed may have accrued somatic and/or
epigenetic alterations that could impact protein localization,
expression and/or function. Accordingly, we performed
indirect immunofluorescence to determine the expres-
sion and localization pattern of each candidate within
the five HL lines. Previous studies from various tumor
types have shown that each candidate normally exhibits
a nuclear-enriched staining pattern within interphase
nuclei. Here we confirm a similar, nuclear-enriched,
focal staining pattern within each of the five HL cell
lines. For example, in L-540 (Figure 2) and HDLM-2
(Additional file 1: Figure S1) each candidate was enriched
within interphase nucleus, but noticeably absent from
nucleoli.
The above observations indicate that protein mis-
localization and epigenetic silencing (i.e. complete silen-
cing) of the candidates are unlikely causes of the cohesion
defects observed within these HL lines. However, they do
not address the possibility that hypo- or hyper-morphic
expression may occur and be a pathogenic event, as has
previously been reported in other tumor types [7,21-24].
Consequently, we evaluated the expression levels of all
six candidates within each of the HL cell lines using
semi-quantitative Western blots (Figure 3). For com-
parison purposes, the abundance of each protein was
first quantified, normalized to the corresponding load-
ing control, and is presented relative to the lymphocytecontrol, which was set to 1.0. Interestingly, five of the
candidates, SMC1A, SMC3, STAG2, Securin and Separase,
were expressed in similar amounts in all five lines investi-
gated. In fact, the overall range of protein expression
varied from a low of 1.1-fold for Securin to 3.3-fold for
STAG2. However, the expression of RAD21 was consid-
erably greater amongst the five HL lines and 23-fold
different – it was lowest in L-428 and L-540 at 0.2-fold
and highest in HDLM-2 at 4.6-fold when compared to
the lymphocyte control. Of particular note is the fact
that the two lines with the highest prevalence of aber-
rant cohesion (~50%), were at the minimal (L-540) and
maximal (HDLM-2) extremes of RAD21 expression. It is
also of interest to note that STAG2 expression is diminished
Figure 3 Expression levels of cohesion-related proteins in HL cell lines. Representative immunoblots depicting the relative expression levels
of 6 specific cohesion-related proteins in a lymphocyte control and five HL cell lines (indicated at top) with α-tubulin serving as a loading control.
Semi-quantitative values for each cohesion epitope were determined and adjusted for unequal loading by generating a ratio with corresponding
loading control. To further facilitate comparisons between cell lines, all semi-quantitative values were normalized to the lymphocyte control
(1st lane in each gel; values set to 1.0) with the relative expression levels indicated.
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relative to the lymphocyte control.
Discussion
Evidence has accrued that implicates aberrant sister
chromatid cohesion as a pathogenic event that causes
CIN, and contributes to the development and progres-
sion of cancer [7]. Despite this information, the preva-
lence of aberrant cohesion within HL, a tumor type that
frequently exhibits CIN, has never been determined. Be-
cause of this, we purposefully limited the current study
to investigations of aberrant cohesion within HL, and
thus, we did not attempt to address the role(s) aberrant
cohesion may have on gene expression and/or DNA re-
pair. In the current study, we evaluated a panel of five
commonly employed aneuploid HL cell lines and show
that each exhibits cohesion defects ranging from 10.2%
to 55.4%. Strikingly, two lines, L-540 and HDLM-2,
harbor defects in ~50% of all mitotic spreads evaluated.
Subsequent semi-quantitative Western blot analyses de-
termined that RAD21 expression varied greatly amongst
all HL lines but were highest in HDLM-2 and lowest
in L-540.
Collectively, our data demonstrate that cohesion defects
are a common feature of all HL lines investigated, but
are particularly prevalent within the HDLM-2 and L-540.
Our study also suggests that aberrant RAD21 expression
may contribute to the high levels of aberrant cohesion
in HDLM-2 and L-540 cells. Although our analyses
cannot preclude de novo mutations that impact the
functions encoded by the six candidate genes evaluated,
data gleaned from the Broad-Novartis Cancer Cell Line
Encyclopedia [44] failed to identify a single somaticmutation in any of the six genes within any of the HL
cell lines. Moreover, our expression and localization data
show that each protein is expressed and exhibits the
expected nuclear-enriched localization pattern indicat-
ing that epigenetic silencing and/or mis-localization of
the six candidates cannot account for the cohesion
defects we observe. It should be noted however, that many
additional proteins impact sister chromatid cohesion
including cohesion loaders, kinases and those involved
in cohesion establishment. For example, we previously
identified novel roles for CDC4/FBXW7 (a classical cell
cycle regulator) and MRE11A (a DNA repair protein)
in cohesion [7]. Thus, it remains formally possible that
aberrant expression of additional cohesion-related pro-
teins may contribute to the aberrant cohesion and CIN
observed in the HL cell lines. Indeed, the differences in
the prevalence and severity of the PCGs between these
lines (see Table 2; predominantly PCGI in HDLM-2 vs.
predominantly PCGIII in L-540) suggest that the under-
lying aberrant mechanism(s) accounting for the cohe-
sion defects are likely to be distinct. Nevertheless, our
findings support a growing body of evidence implicating
aberrant cohesion as a contributing and driving factor
in the development of various cancers, which based on
the current findings, can be expanded to include HL.
It is now becoming apparent that altered expression,
function, and/or localization of cohesin and cohesion-
related proteins causes aberrant cohesion, CIN and is
correlated with various disease states. For example, som-
atic alterations in genes that regulate sister chromatid co-
hesion have been identified in a number of tumor types
including breast, colorectal lung and ovarian cancers,
Ewing’s sarcoma, melanoma, acute myeloid leukemia, and
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contributes to tumorigenesis [7,21-24,26-28,42,44-46].
Four large-scale, gene re-sequencing efforts by the
Cancer Genome Atlas (TCGA) Network identified non-
synonymous single nucleotide polymorphisms (nsSNPs),
homozygous deletions and gene amplifications in breast
[21], colorectal [22], lung [24] and ovarian [23] cancers
(Table 3). Most relevant to the current study is the find-
ing that RAD21 is frequently amplified in two of the
four tumor types evaluated. RAD21 is amplified in 13.9%
(67/482 tumors) of breast tumors evaluated [21], while
it is amplified in 18.0% (57/316 tumors) [23] of ovarian
tumors. In breast cancer, correlations have been identi-
fied between enhanced RAD21 expression [47] (and the
presence of specific nsSNPs [48]) and overall breast
cancer risks, and RAD21 over-expression is associated
with poor prognosis and the acquisition of drug
resistance [47]. Aberrant RAD21 mRNA expression has
also been examined in endometrial cancers where
Supernat et al. [49] noted elevated expression strongly
correlated with more advanced tumor stages and
grades. Finally, RAD21 is amplified and over-expressed
in prostate cancer [50], and its expression is correlated
with invasion and metastasis in oral squamous cell
carcinomas [51]. In agreement with these findings, our
data show that RAD21 expression levels are elevated
in HDLM-2 and are associated with a high prevalence
of aberrant cohesion and CIN. Our results also agree
with recent mRNA expression data indicating that
RAD21 levels are frequently increased in liquid tumors
(Additional file 1: Figure S2). For example, publically
available data from the CCLE_expression_Entrez_2012-10-
18.res: Gene-centric RMA-normalized mRNA expression
data (www.broadinstitute.org/ccle) indicate that RAD21
mRNAs levels from the HL cell lines rank 5th amongst
the 37 different tumor types evaluated (Additional file 1:
Figure S2). Collectively, these data strongly suggest that
RAD21 over-expression may be a pathogenic event in a
variety of tumor types, including HL.Table 3 Somatic alteration in cohesion-related genes in cance
Gene Percentage of somatic alterationsB in
Breast (482C) Colorectal (212C)
nsSNP Del Amp nsSNP Del Am
SMC1A 0.8 0.0 0.0 4.2 0.0 0.0
SMC3 0.2 0.2 0.0 1.4 0.9 0.0
RAD21 0.6 0.0 13.9 2.8 0.0 1.9
STAG2 1.2 0.0 0.0 2.8 0.0 0.0
PTTG1B 0.0 0.4 0.2 0.5 0.0 0.0
ESPL1C 1.5 0.0 0.2 3.3 0.0 0.0
AOnly the Cancer Genome Atlas (TCGA) data is shown [21-24].
Bnon-synonymous single nucleotide polymorphism (nsSNP), homozygous deletion (
CThe total number of tumors sequenced is indicated within parentheses.It is now becoming clear that RAD21 is an excellent
and attractive molecule to study for several reasons. From
a tumorigenic perspective altered RAD21 expression is
associated with a number of tumor types – over-expression
is associated with advanced tumor stage and grade,
enhanced invasion and metastasis, and the acquisition
of multidrug resistance. However, from a therapeutic
targeting perspective, RAD21 is also an attractive can-
didate. For example, Atienza et al. [52] recently showed
that RAD21 suppression decreases cell growth and en-
hances cytotoxicity to two chemotherapeutic agents,
suggesting that chemically targeting RAD21 may hold
therapeutic potential. Consequently, tumors that over-
express RAD21, such as HDLM-2, may be sensitive to
RAD21 suppression. Thus, of the four members of the
cohesin complex members, RAD21 is emerging as a lead
candidate that may predict tumor behavior and thera-
peutic resistance, but it may also represent a candidate
therapeutic target. In light of these findings we believe that
aberrant RAD21 expression, particularly over-expression
in HDLM-2 and perhaps underexpression in L-540 (and
L-428), has a role in the development and progression of
various tumor types, which we have expanded to include
HL. Future studies will be required to elucidate the spe-
cific mechanism(s) by which RAD21 and other cohesion
genes contribute to the development of various tumor
types such as HL.
Conclusions
Despite evidence suggesting that aberrant sister chroma-
tid cohesion is a driver of the tumorigenic process, its
prevalence within HL is unknown. Our data demonstrate
that aberrant cohesion is common to all five HL cell lines
evaluated. They further show that aberrant cohesion is
present in ~50% of all spreads examined for L-540 and
HDLM-2, which also exhibit aberrant RAD21 expres-
sion. Accordingly, we conclude that aberrant cohesion
is a common feature within HL cell lines. Based on this
study and supporting data from other tumor types, werA
Lung (178C) Ovarian (316C)
p nsSNP Del Amp nsSNP Del Amp
1.1 0.0 0.0 1.3 0.0 0.0
2.8 0.6 0.0 0.3 0.0 0.0
1.7 0.0 0.0 0.3 0.6 18.0
3.4 0.0 0.0 0.9 0.0 0.0
1.1 0.6 0.0 0.0 0.0 0.9
4.5 0.0 0.6 0.0 0.3 0.6
Del), gene amplification (Amp).
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http://www.biomedcentral.com/1471-2407/13/391further conclude that aberrant RAD21 expression is a
strong candidate that contributes to the development
of aberrant cohesion, CIN and tumor development in
these cell lines and perhaps HL. Thus, it will be im-
portant to extend the current findings of this study
into patient samples to characterize the prevalence of
aberrant cohesion and aberrant RAD21 expression, and
establish their putative roles as causative agents in the
development of HL.
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